{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:43:53Z","timestamp":1753875833280,"version":"3.41.2"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD028483\/OD\/NIH HHS\/United States","P50 AG005133\/AG\/NIA NIH HHS\/United States","R01 AG027224\/AG\/NIA NIH HHS\/United States","R01 MH116046\/MH\/NIMH NIH HHS\/United States","P30 AG066468\/AG\/NIA NIH HHS\/United States"],"award-info":[{"award-number":["S10 OD028483\/OD\/NIH HHS\/United States","P50 AG005133\/AG\/NIA NIH HHS\/United States","R01 AG027224\/AG\/NIA NIH HHS\/United States","R01 MH116046\/MH\/NIMH NIH HHS\/United States","P30 AG066468\/AG\/NIA NIH HHS\/United States"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Approximately 50% of Alzheimer\u2019s disease (AD) patients will develop psychotic symptoms and these patients will experience severe rapid cognitive decline compared with those without psychosis (AD-P). Currently, no medication has been approved by the Food and Drug Administration for AD with psychosis (AD+P) specifically, although atypical antipsychotics are widely used in clinical practice. These drugs have demonstrated modest efficacy in managing psychosis in individuals with AD, with an increased frequency of adverse events, including excess mortality. We compared the differences between the genetic variations\/genes associated with AD+P and schizophrenia from existing Genome-Wide Association Study and differentially expressed genes (DEGs). We also constructed disease-specific protein\u2013protein interaction networks for AD+P and schizophrenia. Network efficiency was then calculated to characterize the topological structures of these two networks. The efficiency of antipsychotics in these two networks was calculated. A weight adjustment based on binding affinity to drug targets was later applied to refine our results, and 2013 and 2123 genes were identified as related to AD+P and schizophrenia, respectively, with only 115 genes shared. Antipsychotics showed a significantly lower efficiency in the AD+P network than in the schizophrenia network (P\u00a0&amp;lt;\u20090.001) indicating that antipsychotics may have less impact in AD+P than in schizophrenia. AD+P may be caused by mechanisms distinct from those in schizophrenia which result in a decreased efficacy of antipsychotics in AD+P. In addition, the network analysis methods provided quantitative explanations of the lower efficacy of antipsychotics in AD+P.<\/jats:p>","DOI":"10.1093\/bib\/bbac394","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T06:58:32Z","timestamp":1664002712000},"source":"Crossref","is-referenced-by-count":5,"title":["Efficacy difference of antipsychotics in Alzheimer\u2019s disease and schizophrenia: explained with network efficiency and pathway analysis methods"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9814-5085","authenticated-orcid":false,"given":"Peihao","family":"Fan","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kofler","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Biostatistics at the University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Marks","sequence":"additional","affiliation":[{"name":"Center for Neuroscience at the University of Pittsburgh and the Department of Neurobiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Sweet","sequence":"additional","affiliation":[{"name":"UPMC Endowed Professor of Psychiatric Neuroscience and Professor of Neurology at the University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Wang","sequence":"additional","affiliation":[{"name":"department of pharmaceutical sciences, school of pharmacy at University of Pittsburgh , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"issue":"4","key":"2022112111102607600_ref1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002093-200310000-00002","article-title":"Whose quality of life is it anyway?: The validity and reliability of the Quality of Life-Alzheimer's Disease (QoL-AD) scale","volume":"17","author":"Thorgrimsen","year":"2003","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2022112111102607600_ref2","article-title":"World Alzheimer Report","author":"Wimo","year":"2010","journal-title":"The global economic impact of dementia Alzheimer\u2019s Disease International"},{"issue":"11","key":"2022112111102607600_ref3","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1176\/appi.ajp.162.11.2022","article-title":"Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003","volume":"162","author":"Ropacki","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2022112111102607600_ref4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2147\/CIA.S3351","article-title":"Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole","volume":"3","author":"Madhusoodanan","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"Suppl 2","key":"2022112111102607600_ref5","first-page":"5","article-title":"Using antipsychotic agents in older patients","volume":"65","author":"Alexopoulos","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2022112111102607600_ref6","first-page":"26","article-title":"Antipsychotics FOR patients WITH dementia: The road less traveled: Second-generation agents have an important but limited role in treating behavioral and psychological symptoms","volume":"17","author":"Burke","year":"2018","journal-title":"Current Psychiatry"},{"issue":"4","key":"2022112111102607600_ref7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00002512-200219040-00002","article-title":"Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience","volume":"19","author":"Kindermann","year":"2002","journal-title":"Drugs Aging"},{"issue":"Suppl 8","key":"2022112111102607600_ref8","first-page":"43","article-title":"Side effects of antipsychotics in the elderly","volume":"61","author":"Masand","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2022112111102607600_ref9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","article-title":"Impact of FDA black box advisory on antipsychotic medication use","volume":"170","author":"Dorsey","year":"2010","journal-title":"Arch Intern Med"},{"issue":"5","key":"2022112111102607600_ref10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2040622316658463","article-title":"Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses","volume":"7","author":"Tampi","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"2022112111102607600_ref11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/nmt.14.46","article-title":"Agitation and aggression in Alzheimer's disease: an update on pharmacological and psychosocial approaches to care","volume":"5","author":"Gallagher","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"4","key":"2022112111102607600_ref12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5498\/wjp.v4.i4.72","article-title":"Pharmacological management of behavioral symptoms associated with dementia","volume":"4","author":"Madhusoodanan","year":"2014","journal-title":"World J Psychiatry"},{"key":"2022112111102607600_ref13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-pharmtox-010611-134520","article-title":"Systems pharmacology: network analysis to identify multiscale mechanisms of drug action","volume":"52","author":"Zhao","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2022112111102607600_ref14","first-page":"86","article-title":"Emerging applications of network and pathway analysis in drug discovery and development","volume":"11","author":"Ganter","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"15\u201316","key":"2022112111102607600_ref15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2012.05.006","article-title":"Network analysis has diverse roles in drug discovery","volume":"17","author":"Hasan","year":"2012","journal-title":"Drug Discov Today"},{"key":"2022112111102607600_ref16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejmech.2018.10.020","article-title":"Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease","volume":"161","author":"Fang","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2022112111102607600_ref17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.2111","article-title":"Physiologically based precision dosing approach for drug-drug-gene interactions: a simvastatin network analysis","volume":"109","author":"Wojtyniak","year":"2021","journal-title":"Clin Pharm Therap"},{"issue":"4","key":"2022112111102607600_ref18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol Sci"},{"issue":"19","key":"2022112111102607600_ref19","doi-asserted-by":"crossref","first-page":"198701","DOI":"10.1103\/PhysRevLett.87.198701","article-title":"Efficient behavior of small-world networks","volume":"87","author":"Latora","year":"2001","journal-title":"Phys Rev Lett"},{"issue":"3","key":"2022112111102607600_ref20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.pharmthera.2013.01.016","article-title":"Structure and dynamics of molecular networks: A novel paradigm of drug discovery: a comprehensive review","volume":"138","author":"Csermely","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"10","key":"2022112111102607600_ref21","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/s41380-021-01152-8","article-title":"Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease","volume":"26","author":"DeMichele-Sweet","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"6","key":"2022112111102607600_ref22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.58.6.907","article-title":"Increased familial risk of the psychotic phenotype of Alzheimer disease","volume":"58","author":"Sweet","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"2022112111102607600_ref23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.biopsych.2013.08.020","article-title":"Psychosis in Alzheimer\u2019s disease","volume":"75","author":"Murray","year":"2014","journal-title":"Biol Psychiatry"},{"issue":"7510","key":"2022112111102607600_ref24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Ripke","year":"2014","journal-title":"Nature"},{"issue":"27","key":"2022112111102607600_ref25","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1073\/pnas.1617384114","article-title":"qSVA framework for RNA quality correction in differential expression analysis","volume":"114","author":"Jaffe","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2022112111102607600_ref26","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/nn.4156","article-title":"The PsychENCODE project","volume":"18","author":"Akbarian","year":"2015","journal-title":"Nat Neurosci"},{"issue":"D1","key":"2022112111102607600_ref27","doi-asserted-by":"crossref","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","author":"Consortium, T. U","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2022112111102607600_ref28","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"volume-title":"Psychopharmacology","author":"","key":"2022112111102607600_ref29"},{"issue":"9657","key":"2022112111102607600_ref30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"The Lancet"},{"issue":"Database issue","key":"2022112111102607600_ref31","doi-asserted-by":"crossref","first-page":"D412","DOI":"10.1093\/nar\/gkn760","article-title":"STRING 8--a global view on proteins and their functional interactions in 630 organisms","volume":"37","author":"Jensen","year":"2009","journal-title":"Nucleic Acids Res"},{"volume-title":"Proceedings of the 7th Python in Science Conference","year":"2008","author":"Hagberg","key":"2022112111102607600_ref32"},{"issue":"D1","key":"2022112111102607600_ref33","doi-asserted-by":"crossref","first-page":"D808","DOI":"10.1093\/nar\/gks1094","article-title":"STRING v9. 1: protein-protein interaction networks, with increased coverage and integration","volume":"41","author":"Franceschini","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2022112111102607600_ref34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/jmg.2006.041376","article-title":"Predicting disease genes using protein\u2013protein interactions","volume":"43","author":"Oti","year":"2006","journal-title":"J Med Genet"},{"issue":"42","key":"2022112111102607600_ref35","doi-asserted-by":"crossref","first-page":"15148","DOI":"10.1073\/pnas.0404315101","article-title":"Molecular triangulation: bridging linkage and molecular-network information for identifying candidate genes in Alzheimer's disease","volume":"101","author":"Krauthammer","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"2022112111102607600_ref36","doi-asserted-by":"crossref","first-page":"1289259","DOI":"10.1155\/2017\/1289259","article-title":"Drug target protein-protein interaction networks: a systematic perspective","volume":"2017","author":"Feng","year":"2017","journal-title":"Biomed Res Int"},{"issue":"2","key":"2022112111102607600_ref37","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pcbi.0030017","article-title":"Efficiency and cost of economical brain functional networks","volume":"3","author":"Achard","year":"2007","journal-title":"PLoS Comput Biol"},{"issue":"6684","key":"2022112111102607600_ref38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/30918","article-title":"Collective dynamics of \u2018small-world\u2019 networks","volume":"393","author":"Watts","year":"1998","journal-title":"Nature"},{"issue":"5569","key":"2022112111102607600_ref39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1126\/science.1065103","article-title":"Specificity and stability in topology of protein networks","volume":"296","author":"Maslov","year":"2002","journal-title":"Science"},{"issue":"5594","key":"2022112111102607600_ref40","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.298.5594.824","article-title":"Network motifs: simple building blocks of complex networks","volume":"298","author":"Milo","year":"2002","journal-title":"Science"},{"key":"2022112111102607600_ref41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fnins.2016.00308","article-title":"Altered Cerebral Blood Flow Covariance Network in Schizophrenia","volume":"10","author":"Liu","year":"2016","journal-title":"Front Neurosci"},{"issue":"5","key":"2022112111102607600_ref42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/brain.2011.0038","article-title":"The ubiquity of small-world networks","volume":"1","author":"Telesford","year":"2011","journal-title":"Brain Connect"},{"issue":"6","key":"2022112111102607600_ref43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"2022112111102607600_ref44","article-title":"Benzodiazepines for schizophrenia","volume":"11","author":"Dold","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2022112111102607600_ref45","first-page":"300","volume-title":"Proceedings of the 2017 2nd International Conference on Modelling, Simulation and Applied Mathematics (MSAM2017)","author":"Zhang","year":"2017"},{"issue":"5","key":"2022112111102607600_ref46","doi-asserted-by":"crossref","first-page":"057101","DOI":"10.1103\/PhysRevE.71.057101","article-title":"Network clustering coefficient without degree-correlation biases","volume":"71","author":"Soffer","year":"2005","journal-title":"Phys Rev E"},{"issue":"5","key":"2022112111102607600_ref47","doi-asserted-by":"crossref","first-page":"100052","DOI":"10.1016\/j.patter.2020.100052","article-title":"Integrated value of influence: an integrative method for the identification of the most influential nodes within networks","volume":"1","author":"Salavaty","year":"2020","journal-title":"Patterns"},{"key":"2022112111102607600_ref48","first-page":"171","article-title":"Critical values and probability levels for the Wilcoxon rank sum test and the Wilcoxon signed rank test","volume":"1","author":"Wilcoxon","year":"1970","journal-title":"Selected tables in mathematical statistics"},{"issue":"D1","key":"2022112111102607600_ref49","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2022112111102607600_ref50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-30634-6_6","volume-title":"Introduction to nonparametric statistics for the biological sciences using R","author":"MacFarland","year":"2016"},{"issue":"4","key":"2022112111102607600_ref51","first-page":"Cd010631","article-title":"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia","volume":"4","author":"Saha","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2022112111102607600_ref52","doi-asserted-by":"crossref","first-page":"EBO. S10686","DOI":"10.4137\/EBO.S10686","article-title":"A unifying mathematical framework for genetic robustness, environmental robustness, network robustness and their trade-offs on phenotype robustness in biological networks. Part III: synthetic gene networks in synthetic biology","volume":"9","author":"Chen","year":"2013","journal-title":"Evol Bioinform"},{"issue":"3","key":"2022112111102607600_ref53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3233\/JAD-140579","article-title":"The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials","volume":"42","author":"Ma","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2022112111102607600_ref54","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer\u2019s disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"8","key":"2022112111102607600_ref55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2022112111102607600_ref56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"28","author":"Conley","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"2022112111102607600_ref57","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1517\/14656566.7.13.1825","article-title":"Sertindole: efficacy and safety in schizophrenia","volume":"7","author":"Lindstr\u00f6m","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2022112111102607600_ref58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"},{"key":"2022112111102607600_ref59","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"2022112111102607600_ref60","doi-asserted-by":"crossref","DOI":"10.4103\/0973-1229.58825","article-title":"Stahl\u2019s Essential psychopharmacology: neuroscientific basis and practical applications","volume-title":"Mens Sana Monographs","author":"Andrade"},{"issue":"3","key":"2022112111102607600_ref61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia\u2014a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"2022112111102607600_ref62","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2014.00171","article-title":"Systemic inflammation, blood-brain barrier vulnerability and cognitive\/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy","volume":"6","author":"Takeda","year":"2014","journal-title":"Front Aging Neurosci"},{"volume-title":"Front Neurosci","author":"M\u00fcller","key":"2022112111102607600_ref63"},{"issue":"1","key":"2022112111102607600_ref64","first-page":"1","article-title":"Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care","volume":"2","author":"Ralph","year":"2018","journal-title":"J Alzheimer Dis"},{"issue":"3","key":"2022112111102607600_ref65","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11595","article-title":"Effects of antipsychotics on secular mortality trends in patients with Alzheimer's disease","volume":"79","author":"Nielsen","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2022112111102607600_ref66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eurpsy.2016.11.013","article-title":"Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer's dementia","volume":"42","author":"Nielsen","year":"2017","journal-title":"Eur Psychiatry"},{"issue":"2","key":"2022112111102607600_ref67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40501-017-0114-0","article-title":"Targeting the immune system with pharmacotherapy in schizophrenia","volume":"4","author":"Melbourne","year":"2017","journal-title":"Curr Treat Options Psychiatry"},{"issue":"10","key":"2022112111102607600_ref68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013701","article-title":"Comparing brain networks of different size and connectivity density using graph theory","volume":"5","author":"Van Wijk","year":"2010","journal-title":"PLoS One"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/23\/6\/bbac394\/47144063\/bbac394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bib\/article-pdf\/23\/6\/bbac394\/47144063\/bbac394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T11:11:25Z","timestamp":1669029085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbac394\/6712703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbac394","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"type":"print","value":"1467-5463"},{"type":"electronic","value":"1477-4054"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,9,24]]},"article-number":"bbac394"}}